A review of miRNAs accuracy as a diagnostic biomarker in COPD patients
Downloads
Introduction: Chronic Obstructive Pulmonary Disease (COPD) is the third highest leading cause of early death amongst other non-communicable diseases characterized by irreversible limitations of airflow. Current reliable classification relies on forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) measured on spirometry. In order to provide more effective and individualized management, new markers are needed. Accumulating studies has shown the role of miRNA in the pathogenesis of COPD and the progression of the disease. This review aims to provide overview of the diagnostic capabilities of miRNA and identify gaps of knowledge for further studies.
Methods: A review based on Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) was conducted with the database from Pubmed, Science Direct, and Proquest using the key word ("mirna" or "microrna") AND ("copd" or "chronic obstructive pulmonary disease") and diagnostic. Inclusion criteria includes studies that reported diagnostic accuracy of miRNA in patients within the last 10 years.
Results: A total of nine studies has reported diagnostic accuracies of miRNA in distinguishing COPD and normal, COPD and AECOPD, and other subtypes of COPD
Conclusion: Retrospective diagnostic analyses of miRNAs have shown several promising AUC and need to be followed up with reliable prospective designs. Further diagnostics studies, in particular those with clinical values, need to be conducted.
Ahmed R, Robinson R, Mortimer K. The epidemiology of noncommunicable respiratory disease in sub-Saharan Africa, the Middle East, and North Africa. Malawi Med J 2017; 29: 203–211.
PERHIMPUNAN DOKTER PARU INDONESIA. Pers Release Perhimpunan Dokter Paru Indonesia dalam rangka WORLD COPD DAY 2018, https://www.klikpdpi.com/index.php?mod=article&sel=8720 (2020).
Riley CM, Sciurba FC. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA 2019; 321: 786–797.
Salimian J, Mirzaei H, Moridikia A, et al. Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers. J Res Med Sci 2018; 23: 27.
Soeda S, Ohyashiki JH, Ohtsuki K, et al. Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease. Int J Mol Med 2013; 31: 533–539.
Kara M, Kirkil G, Kalemci S. Differential Expression of MicroRNAs in Chronic Obstructive Pulmonary Disease. Adv Clin Exp Med Off organ Wroclaw Med Univ 2016; 25: 21–26.
Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: A Wiley-Interscience Publication, 2013.
Alvanegh AG, Tavallaei M, Edalat H. Severe decline in mir-20a and mir-92a in the context of the mir-17-92 cluster: Ideal biomarkers of various COPD subtypes. Acta Med Iran 2019; 57: 17–26.
Leidinger P, Keller A, Borries A, et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer 2011; 74: 41–47.
Abd Elfattah N, Ali-Labib R. MicroRNA7 expression in exhaled breath condensate of smokers with chronic obstructive pulmonary disease: A potential biomarker? Egypt J Chest Dis Tuberc 2017; 66: 577–580.
Hu H-L, Nie Z-Q, Lu Y, et al. Circulating miR-125b but not miR-125a correlates with acute exacerbations of chronic obstructive pulmonary disease and the expressions of inflammatory cytokines. Medicine (Baltimore) 2017; 96: e9059.
Liu X, Qu J, Xue W, et al. Bioinformatics-based identification of potential microRNA biomarkers in frequent and non-frequent exacerbators of COPD. Int J COPD 2018; 13: 1217–1228.
Bertrams W, Griss K, Han M, et al. Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation. Sci Rep 2020; 10: 1–9.
Asensio VJ, Tomás A, Iglesias A, et al. Eosinophilic COPD Patients Display a Distinctive Serum miRNA Profile From Asthma and Non-eosinophilic COPD. Arch Bronconeumol 2020; 56: 234–241.
Donaldson A, Natanek SA, Lewis A, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 2013; 68: 1140–1149.
Fujii T, Shimada K, Nakai T, et al. MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy. J Clin Med 2018; 7: 98.
MacIntyre N, Yuh CH. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 530–535.
Husebí¸ GR, Grí¸nseth R, Lehmann S, et al. Pneumonia vs non-pneumonia in COPD exacerbations – different risks? Eur Respir J 2018; 52: PA2277.
Kolsum U, Ravi A, Hitchen P, et al. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res 2017; 18: 73.
López-Baltanás R, Encarnación Rodríguez-Ortiz M, Canalejo A, et al. Magnesium supplementation reduces inflammation in rats with induced chronic kidney disease. Eur J Clin Invest 2021; e13561.
Keller A, Fehlmann T, Ludwig N, et al. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics Proteomics Bioinformatics 2018; 16: 162–171.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
